CareDx: Conservative Revenue Upside Offset by Weaker Margins and Coverage Uncertainty Justifying Hold Rating

William Blair analyst Andrew Brackmann has reiterated their neutral stance on CDNA stock, giving a Hold rating on February 12.

Andrew Brackmann has given his Hold rating due to a combination of factors, including that CareDx’s fourth-quarter results matched its earlier preannouncement and 2026 guidance that modestly exceeded consensus on revenue, testing volumes, and digital/product sales. He views the revenue outlook as conservative enough to allow for potential upside, even after accounting for the anticipated $7.5 million reimbursement headwind tied to the final local coverage determination and limited contribution from transplant volume growth or Epic integrations.

At the same time, Brackmann notes that the company’s AEBITDA margin outlook of about 9% is slightly weaker than what the market had expected, which tempers the otherwise constructive top-line story. In his view, the shares are unlikely to break out meaningfully until investors gain greater visibility on the finalized coverage decision, creating a near-term cap on valuation and justifying the decision to maintain a Market Perform, or Hold, recommendation.

According to TipRanks, Brackmann is a 4-star analyst with an average return of 16.1% and a 59.46% success rate. Brackmann covers the Healthcare sector, focusing on stocks such as Adaptive Biotechnologies, BillionToOne, Inc. Class A, and Tempus AI, Inc. Class A.